A recent study reveals that patients who come off blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who stop conventional lifestyle regimens.
Findings released in a leading medical journal points out that while obese people frequently drop about a fifth of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month once they quit.
"People purchasing these treatments need to be cognizant of the danger of rapid rebound weight gain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
This pace of regain means a return to original weight within about one and a half years.
Weighing Therapies
The study, which examined dozens of studies involving thousands of participants, compared the results of the injectable medications with other pills.
Researchers note that people who lose weight through dieting generally see a more gradual weight regain—around 0.1 kg a month—post-intervention.
Understanding the Quick Rebound
Doctors suggest the mode of action of the drugs is key to understanding the accelerated regain.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing the hormone levels several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement results in appetite is unsuppressed, making overeating far more likely."
An Ongoing Issue?
The NHS recommend the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the likelihood of weight regain, the therapy should be considered long-term.
This perspective is reinforced by drug manufacturers, who say that the findings "underscore the long-term character of excess weight," akin to managing conditions like diabetes.
User Accounts
Users who have stopped the jabs explain a sudden return of cravings.
"It felt as if a trigger activating and you're instantly ravenous," described an individual.
This challenge is compounded if patients have not adopted lasting dietary or behavioural changes during treatment.
Growing Interest
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among females than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic fix and long-term success hinges on combined lifestyle support.
